Applications of large language models in cancer care: current evidence and future perspectives.
ChatGPT
artificial intelligence
cancer care
chatbot
large language models
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
07
2023
accepted:
21
08
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
The development of large language models (LLMs) is a recent success in the field of generative artificial intelligence (AI). They are computer models able to perform a wide range of natural language processing tasks, including content generation, question answering, or language translation. In recent months, a growing number of studies aimed to assess their potential applications in the field of medicine, including cancer care. In this mini review, we described the present published evidence for using LLMs in oncology. All the available studies assessed ChatGPT, an advanced language model developed by OpenAI, alone or compared to other LLMs, such as Google Bard, Chatsonic, and Perplexity. Although ChatGPT could provide adequate information on the screening or the management of specific solid tumors, it also demonstrated a significant error rate and a tendency toward providing obsolete data. Therefore, an accurate, expert-driven verification process remains mandatory to avoid the potential for misinformation and incorrect evidence. Overall, although this new generative AI-based technology has the potential to revolutionize the field of medicine, including that of cancer care, it will be necessary to develop rules to guide the application of these tools to maximize benefits and minimize risks.
Identifiants
pubmed: 37731643
doi: 10.3389/fonc.2023.1268915
pmc: PMC10507617
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1268915Informations de copyright
Copyright © 2023 Iannantuono, Bracken-Clarke, Floudas, Roselli, Gulley and Karzai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Brief Bioinform. 2022 Nov 19;23(6):
pubmed: 36156661
Science. 2023 Jan 27;379(6630):313
pubmed: 36701446
BMJ Health Care Inform. 2023 Jun;30(1):
pubmed: 37399360
Cureus. 2023 Apr 21;15(4):e37938
pubmed: 37220429
NPJ Breast Cancer. 2023 May 30;9(1):44
pubmed: 37253791
JAAD Int. 2023 Jun 09;12:168-170
pubmed: 37404248
J Cancer Res Clin Oncol. 2023 Sep;149(11):9505-9508
pubmed: 37160626
Lancet Digit Health. 2023 Mar;5(3):e107-e108
pubmed: 36754724
JNCI Cancer Spectr. 2023 Mar 1;7(2):
pubmed: 36929393
N Engl J Med. 2023 Mar 30;388(13):1201-1208
pubmed: 36988595
Cancer Discov. 2021 Apr;11(4):900-915
pubmed: 33811123
N Engl J Med. 2023 Mar 30;388(13):1233-1239
pubmed: 36988602
Ann Surg Oncol. 2023 Oct;30(11):6284-6286
pubmed: 37349615
Healthcare (Basel). 2023 Mar 19;11(6):
pubmed: 36981544
J Transl Med. 2023 Apr 19;21(1):269
pubmed: 37076876
AJR Am J Roentgenol. 2023 Aug 16;:1-4
pubmed: 37222278
JMIR Cancer. 2021 Nov 29;7(4):e27850
pubmed: 34847056
Radiology. 2023 May;307(4):e230424
pubmed: 37014239
Cancer. 2023 Aug 1;129(15):2284-2289
pubmed: 37183438
Nature. 2023 Feb;614(7947):224-226
pubmed: 36737653
Clin Mol Hepatol. 2023 Jul;29(3):721-732
pubmed: 36946005
Radiology. 2023 Jun;307(5):e230922
pubmed: 37310252
Urology. 2023 Jul 4;:
pubmed: 37406864